NCT06220032 2026-01-05
HO170DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Recruiting
Clinical Trials
14 trialsNCT07255963 2025-12-01
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT07034508 2025-06-24
A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT04113226 2023-02-08
Relyage
Centre Hospitalier Universitaire, Amiens
Phase 2 Unknown
NCT03064867 2022-11-16
Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Case Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT02531308 2022-09-28
DLBCL
Rush University Medical Center
Phase 2 Terminated
NCT00003716 2022-05-31
Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression Therapy
Stanford University
Phase 2 Completed
NCT00553943 2018-08-23
Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis
Lymphoma Study Association
Phase 2 Completed
NCT00867529 2018-01-02
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00983944 2017-11-30
Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Withdrawn
NCT01282476 2017-05-09
Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Massachusetts General Hospital
Phase 2 Terminated
NCT00799136 2013-09-12
CATCH
Ontario Clinical Oncology Group (OCOG)
Phase 2 Completed
NCT00087009 2013-03-19
Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
Phase 1 Terminated
NCT00980304 2009-09-21
R Retreatment in 1st Relapsed DLBCL
Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown